MBD is a leader in engineering standardized 3D organoids for personalized medicine, utilizing innovative 3D culture technology and a high-throughput screening (HTS) system. Our flagship technology addresses key challenges in organoid culture?automation, robustness, scalability, and easy imaging?ushering in a new era in drug development. We simplify organoid-based research with the Pillar method, enabling standardized, reproducible 3D organoid cultures that closely replicate cellular heterogeneity, structure, and function of primary samples. The fully automated HTS system provides rapid, consistent results to identify the most effective drugs. Our technology specializes in culturing patient-derived cancer cells into 3D organoids, enabling high-throughput drug screening to find the most effective anti-cancer treatments. We have successfully launched a commercial personalized medicine service for anti-cancer drug sensitivity testing.
moreEXHIBIT
ASFA Spotter
The All-in-One liquid handling system enables precise small-volume dispensing of cells, drugs, viruses, and viscous samples like ECM, automating 3D organoid culture for cell biology research and drug screening. 1. Air Pressure Dispensing: Uses air pressure pulse, not a fixed nozzle syringe. 2. Dead Volume Below 3μL (vs. 40μL in fixed nozzles). 3. Nano-Class Precision (CV 5%): Drugs: 20?2000nL / Viscous: 40?5000nL. 4. On-the-Fly Mode: Non-contact, high-speed dispensing. 5. FDA, CE certified.
More
COMPANY INTRODUCTION
MBD is a leader in engineering standardized 3D organoids for personalized medicine, utilizing innovative 3D culture technology and a high-throughput screening (HTS) system. Our flagship technology addresses key challenges in organoid culture?automation, robustness, scalability, and easy imaging?ushering in a new era in drug development. We simplify organoid-based research with the Pillar method, enabling standardized, reproducible 3D organoid cultures that closely replicate cellular heterogeneity, structure, and function of primary samples. The fully automated HTS system provides rapid, consistent results to identify the most effective drugs. Our technology specializes in culturing patient-derived cancer cells into 3D organoids, enabling high-throughput drug screening to find the most effective anti-cancer treatments. We have successfully launched a commercial personalized medicine service for anti-cancer drug sensitivity testing.
